Inhibition of the binding human IgE to its receptor by tetracyclic compounds for the alleviation of IgE-mediated immune response
US5965605A · kind A · utility
7Cited by
1References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 29, 1997 |
| Grant date | Oct 12, 1999 |
| Priority date | — |
| Expiry date | Dec 29, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D311/82
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are chemical agents with unexpected activity to inhibit the interactions between human immunoglobulin E (IgE) and its receptor (Fc.epsilon.RI) which interactions are known to be involved in triggering allergic responses. The agents may be used to module the allergic response in the treatment of various clinical conditions, including rhinitis, asthma, urticaria, atopic dermatitis, and anaphylacric shock. The agents can be formulated for oral, topical or parenteral administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.